Loading...
OTCM
RLXXF
Market cap71bUSD
Oct 20, Last price  
39.15USD
Name

Relx PLC

Chart & performance

D1W1MN
OTCM:RLXXF chart
P/E
25.92
P/S
5.58
EPS
1.13
Vol. 1Y
—
Shs. 5Y
-0.99%
Rev. 5Y
6.17%
Div Yld LY
—
Div Yld TTM
—
Revenues
9.59b
+1.65%
2,385,261,0002,424,936,0002,821,686,0003,211,559,0003,203,095,0003,175,058,0006,116,000,0006,035,000,0005,773,000,0005,971,000,0006,895,000,0007,355,000,0007,492,000,0007,874,000,0007,110,000,0007,244,000,0008,553,000,0009,161,000,0009,434,000,0009,590,000,000
Net income
2.07b
+6.77%
298,905,000848,252,000172,411,000177,724,000261,346,000290,548,0001,069,000,0001,110,000,000955,000,0001,008,000,0001,161,000,0001,659,000,0001,422,000,0001,505,000,0001,224,000,0001,471,000,0001,634,000,0001,781,000,0001,934,000,0002,065,000,000
CFO
2.88b
+10.28%
585,000,000829,000,000-11,000,000-8,000,000-5,000,000-3,000,0001,407,000,0001,386,000,0001,377,000,0001,407,000,0001,682,000,0001,848,000,0001,985,000,0002,089,000,0001,596,000,0002,016,000,0002,401,000,0002,457,000,0002,608,000,0002,876,000,000
Dividend
May 07, 20260.64694 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Headquartered in London, United Kingdom, and established in 1903, RELX PLC (which rebranded from Reed Elsevier PLC in July 2015) offers sophisticated information analytics and decision-support tools to professional and business clientele across North America, Europe, and other international markets. Its operations are organized into four distinct divisions. The Risk division specializes in delivering analytics and decision systems that blend public and industry-specific data with advanced technology and algorithms, enabling clients to evaluate and anticipate various risks. The Scientific, Technical & Medical segment furnishes essential information and analytical insights to institutions and professionals, facilitating scientific advancement and improvements in healthcare. Within the Legal segment, the company supplies legal, regulatory, and commercial information and analytics, empowering customers' decision-making processes and enhancing their productivity. Lastly, the Exhibitions segment manages events, integrating in-person experiences with data and digital technologies to assist clients in understanding markets, identifying products, and closing deals.

Related entities

Subsidiaries (53)
ELSEVIER INC.
ICIS BENCHMARKING EUROPE B.V.
MACK-BROOKS EXHIBITIONS LIMITED
REED EXHIBITIONS LIMITED
REED EXPOSITIONS FRANCE
RELX (UK) LIMITED
RELX CAPITAL INC.
RELX FINANCE LIMITED
RELX GROUP PLC
RELX INC.
RELX OVERSEAS HOLDINGS LIMITED
AGRM SOLUTIONS C.V.
BUTTERWORTHS LIMITED
ELSEVIER (SINGAPORE) PTE. LTD.
Elsevier A/S
ELSEVIER B.V.
ELSEVIER ESPAÑA SL
ELSEVIER LIMITED
ELSEVIER MASSON SAS
FIRCOSOFT

Key people

Non-Executive Chairman of the Board · since 2022
Chief Executive Officer, Executive Director · since 2009
Chief Financial Officer, Executive Director · since 2014
Chief Executive Officer - Scientific, Technical and Medical · since 2022
Director - RELX Corporate Affairs and Chairman of Elsevier · since 2011
Hugh Jones
Chief Executive Officer - Exhibitions · since 2020
Mark Kelsey
Chief Executive Officer - Risk · since 2020
Vijay Raghavan
Chairman of RELX Technology Forum and Chief Technology Officer - Risk · since 2023
Shweta Vyas
Chief Strategy Officer · since 2025
Chief Legal Officer, Company Secretary · since 2011
Andy Halford
Non-Executive Director · since 2025
Non-Executive Independent Director · since 2023
Non-Executive Independent Director · since 2020
Charlotte Hogg
Non-Executive Independent Director · since 2019
Non-Executive Independent Director · since 2019
Bianca Tetteroo
Non-Executive Independent Director - Workforce Engagement Director · since 2024
Senior Non-Executive Independent Director · since 2023
IPO date
Apr 21, 1948
Employees
33,200
Domiciled in
GB
Incorporated in
GB
Headquarters & legal address
1-3 STRAND
LONDON, LND WC2N 5JR
GB
Previous name
REED ELSEVIER PLC

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT